Donna Mendrick

Donna Mendrick:

Dr. Donna L. Mendrick is the Director of the Division of Systems Biology at the National Center for Toxicology Research (NCTR), a research arm of the FDA.  Her division incorporates genomics, proteomics, metabolomics, bioinformatics and in silico modeling approaches to answer the needs of the FDA in terms of drug and food safety and improving the understanding of human disease.   Her FDA committee assignments include the Senior Science Council, Critical Path Steering Committee, Tox21, and the Interagency Coordination Committee on the Validation of Alternative Methods (ICCVAM).  Dr. Mendrick is a member of the Society of Toxicology’s Disease Prevention Task Force and Secretary/Treasurer of the SOT’s Drug Discovery Toxicology Specialty Section.

She was an Assistant Professor of Pathology at Harvard Medical School and Brigham and Women’s Hospital.  She joined Human Genome Sciences and, as a Group Leader in Pharmacology, oversaw multiple project teams, toxicity studies, pharmacology studies, etc.  Prior to joining the FDA, she was a Scientific Fellow and Vice President of Pharmacogenomics at Gene Logic where she oversaw pharmacogenomics and spearheaded its toxicogenomics effort.  For the latter, she formed a pharmaceutical consortium to help guide the development of the program.  Dr. Mendrick has over 25 years of experience in the fields (in alphabetical order) of immunology, pathology, pharmacogenomics, pharmacology, toxicology and toxicogenomics employing small molecule drugs, recombinant therapeutic proteins and monoclonal antibodies

Dr. Mendrick has published on the use of pharmacogenomics, metabolomics and proteomics to identify biomarkers.  She currently is a committee member of the Predictive Toxicology Discussion Group at the New York Academy of Sciences and is past President of the National Capital Area Chapter of the Society of Toxicology.  Dr. Mendrick was on the Editorial Board of the Journal of Histochemistry and Cytochemistry for 8 years, a member of the NIH SBIR Immunology Study Section for 8 years and a member of the Board of Directors of the National Kidney Foundation of Massachusetts for 4 years.